AVC-102

N/A

Report date: 2024/01/03 15:23:38

Base Information

Drug NameAVC-102

Drug Alias NameUniCAR-T-PSMATMpPSMAUniCAR02-T-pPSMAAVC-102

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsKidney NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[5]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAvenCell Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesN/A

Active IndicationsKidney NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[5]

Inactive IndicationsN/A

Other Information

ATC CodeN/A